Most people who have been told they have eczema have been told very little else. The word functions as a diagnosis, a description, and sometimes an explanation — all at once, and not quite accurately as any of them.
What "eczema" actually is, in clinical terms, is an umbrella. It describes a group of skin conditions that share surface-level similarities — inflammation, itching, disrupted skin barrier — but have different underlying causes, different triggers, and critically, different treatment approaches. Treating all of them the same way is one of the most common reasons people with skin inflammation spend years managing symptoms without addressing what's actually driving them.
The distinction that matters most — the one that changes what your treatment should look like — is between atopic dermatitis and the other conditions grouped under the eczema umbrella. This post explains what that distinction is, why it exists, and what it means in practice.
What "Eczema" Actually Means
The word eczema comes from the Greek for "to boil over" — a description of the weeping, inflamed skin that characterises these conditions at their worst. In modern clinical use, it has become a catch-all for several distinct diagnoses that share certain external features.
The conditions typically grouped under the eczema umbrella include:
Atopic dermatitis — the most common form, and the one most people mean when they say "eczema." Driven by immune dysfunction and a disrupted skin barrier. Often runs in families alongside asthma and hay fever.
Contact dermatitis — inflammation triggered by direct contact with an external substance. Subdivided into irritant contact dermatitis (caused by physical damage from chemicals, detergents, or friction) and allergic contact dermatitis (an immune-mediated reaction to a specific allergen such as nickel, fragrance, or latex).
Dyshidrotic eczema — small, intensely itchy blisters that form on the palms, fingers, and soles. Often associated with stress, heat, or contact with certain metals.
Nummular eczema — coin-shaped patches of inflamed, dry skin, typically appearing on the arms and legs. More common in older adults and in dry climates.
Seborrheic dermatitis — scaly, greasy patches in areas rich in sebaceous glands — scalp, eyebrows, sides of the nose, behind the ears. Linked to Malassezia yeast overgrowth rather than the immune pathways that drive atopic dermatitis.
Stasis dermatitis — inflammation in the lower legs caused by poor venous return, common in people with varicose veins or chronic venous insufficiency.
These are not interchangeable diagnoses. They look similar on the surface — itchy, inflamed skin — but their causes, their natural histories, and their treatments are meaningfully different. A treatment that works for one may be irrelevant, ineffective, or counterproductive for another.
What Makes Atopic Dermatitis Different
Atopic dermatitis (AD) is an immune-mediated, chronic inflammatory skin disease. Understanding what that means is key to understanding why it behaves differently from other forms of eczema and why it requires a different treatment approach.
The Immune Mechanism
In atopic dermatitis, the immune system is dysregulated in a specific direction. The condition is driven predominantly by overactivation of the Th2 immune pathway — a branch of the immune system normally involved in responses to parasites and allergens. In people with AD, this pathway becomes chronically overactive in the skin, producing inflammatory signals — particularly the cytokines IL-4, IL-13, and IL-31 — that drive the inflammation, barrier disruption, and intense itch that characterise the condition.
This Th2 overactivation is not caused by any single external trigger. It is a systemic immune tendency — which is why atopic dermatitis is considered part of a larger pattern called the atopic triad: the co-occurrence of eczema, asthma, and allergic rhinitis (hay fever) in the same individual or family. These three conditions share the same underlying immune overactivation. People with atopic dermatitis are significantly more likely to have asthma and hay fever than the general population, and their children are significantly more likely to develop all three.
The Skin Barrier Defect
Alongside the immune dysfunction, atopic dermatitis involves a structural defect in the skin barrier. Mutations in the gene encoding filaggrin — a protein essential for maintaining the skin's outer protective layer — are the most well-characterised genetic risk factor for atopic dermatitis, found in approximately 30% of patients with the condition.
Filaggrin deficiency means the skin cannot retain moisture effectively and cannot block the entry of allergens and irritants from the environment. This creates a cycle: a leaky barrier allows environmental allergens to penetrate the skin, provoking immune responses that drive inflammation; the resulting inflammation further damages the barrier; the worsened barrier allows more allergens in, perpetuating the cycle.
This is why moisturisation is not optional in atopic dermatitis management — it is a therapeutic intervention that directly addresses one limb of the pathological cycle.
The Microbiome Component
People with atopic dermatitis have a disrupted skin microbiome. The bacterium Staphylococcus aureus — which colonises the skin of the majority of AD patients in significantly higher proportions than in healthy skin — is not merely a bystander. Staph aureus produces toxins that act as superantigens, directly stimulating the immune response and perpetuating inflammation. Flares of atopic dermatitis often coincide with surges in staph aureus colonisation. This is why some AD management strategies include targeted antimicrobial approaches, and why bleach baths — dilute sodium hypochlorite — have clinical evidence behind them as an adjunct treatment.
Why the Distinction Matters for Treatment
If atopic dermatitis has a specific underlying biology — Th2 immune overactivation, barrier defect, microbiome disruption — then effective treatment must address that biology, not just the visible skin inflammation.
This is where the umbrella problem causes real-world harm.
Treating Contact Dermatitis Like Atopic Dermatitis
Contact dermatitis — particularly irritant contact dermatitis — does not involve the same immune pathways as atopic dermatitis. Its treatment priority is identifying and eliminating the offending substance. No amount of immune-modulating therapy will resolve contact dermatitis if the patient continues to be exposed to the trigger.
Patch testing is the diagnostic tool for allergic contact dermatitis — a systematic application of suspected allergens to the skin, read at 48 and 96 hours, which identifies the specific substances driving the reaction. Without patch testing, the cause remains guesswork and the patient manages symptoms indefinitely rather than addressing the source.
Patients with contact dermatitis who are treated with the same approach as atopic dermatitis — long-term topical steroids or immunomodulators — will partially respond (because inflammation is being suppressed) but will not resolve, because the cause is still present. Identifying the contact allergen — nickel in jewellery, fragrance in skincare, preservatives in wet wipes — and removing it is often curative in a way that no amount of topical treatment will be.
Treating Seborrheic Dermatitis as Atopic Dermatitis
Seborrheic dermatitis has a fungal driver — Malassezia yeast overgrowth in sebum-rich skin areas — and responds to antifungal treatment. Topical steroids may reduce the visible inflammation temporarily, but they do not address the fungal component and may, with prolonged use in areas like the face, cause steroid-related side effects without achieving lasting control.
The clinical pattern that distinguishes seborrheic dermatitis includes its distribution (scalp, nasolabial folds, eyebrows, post-auricular areas), its greasy rather than dry scale, and its tendency to respond well to antifungal shampoos and creams. Misclassified as atopic dermatitis, patients with seborrheic dermatitis often cycle through multiple topical immunomodulators without sustained improvement.
What Atopic Dermatitis Actually Requires
Because atopic dermatitis is immune-mediated and chronic, its treatment requires a different framework — one that manages the underlying immune dysfunction rather than only suppressing its surface manifestations.
Emollients and barrier repair are foundational. Applied consistently and generously — not sparingly when the skin feels dry — they directly address the barrier defect that perpetuates the disease cycle. The clinical evidence supports frequent, liberal emollient use as a genuine disease-modifying intervention in AD, not simply symptom management.
Topical corticosteroids are the most widely used anti-inflammatory treatment for flares. They are effective, fast-acting, and well-characterised in terms of potency and side-effect profile. The clinical issue is long-term use — particularly on the face, neck, and skin folds, where atrophy, telangiectasia, and tachyphylaxis (loss of response with repeated use) become relevant. Topical corticosteroid use requires appropriate potency matching to site and age, clear guidance on duration of application, and a plan for stepping down.
Calcineurin inhibitors (tacrolimus, pimecrolimus) are steroid-sparing topical immunomodulators that directly target the Th2-driven inflammation without the atrophy risk of steroids. They are particularly useful on the face and skin folds where steroid use is limited by side-effect profile. Initial burning on application — common and transient — is worth telling patients about in advance to prevent premature discontinuation.
NB-UVB phototherapy is a highly effective systemic immune modulator for moderate-to-severe or widespread atopic dermatitis. The mechanism is specific: 311nm ultraviolet light penetrates the skin and directly modulates the Th2 immune response driving AD, suppressing the inflammatory cytokines responsible for the itch-scratch cycle and barrier disruption. It also has a secondary effect on Staphylococcus aureus colonisation — UV light at therapeutic doses reduces staph burden on the skin surface, addressing another driver of disease perpetuation.
NB-UVB is particularly valuable in AD patients with widespread disease who cannot achieve adequate control with topicals alone, who require ongoing steroid use with associated risks, or who prefer not to use systemic immunosuppressants or biologics. Evidence consistently supports its efficacy in chronic, widespread AD that has failed or outgrown topical-only management.
Biologics — most notably dupilumab, a monoclonal antibody that directly blocks IL-4 and IL-13 signalling — have transformed the treatment of moderate-to-severe atopic dermatitis in recent years. They are highly effective and remarkably well-tolerated. Their limitation in the Indian context is primarily cost and access; for patients who can access them, they represent the most targeted available intervention for the Th2 immune pathway driving AD.
The Atopic March: What It Means for Families
One of the most clinically important features of atopic dermatitis is what is known as the atopic march — the tendency for atopic disease to evolve over time, typically beginning with eczema in infancy, followed by the development of food allergies in early childhood, then allergic rhinitis, and then asthma in later childhood and adolescence.
This pattern is not universal, but it is common enough to be a standard part of the clinical picture. Parents of children with early-onset atopic dermatitis should understand that their child has an immune tendency that may manifest in these other ways, and that this is not a collection of separate bad luck but a single immune phenotype expressing itself across different organ systems at different developmental stages.
Aggressive early management of atopic dermatitis — particularly barrier repair — has been studied as a potential intervention to slow or interrupt the atopic march. The evidence is still developing, but it adds clinical weight to taking early-onset AD seriously and treating it actively rather than managing it conservatively until it becomes severe.
How to Know Which Type You Have
If you have been told you have "eczema" without further specification, these questions are worth raising with your dermatologist:
Where does it appear? Distribution is the first clinical differentiator. Skin folds, wrists, and the backs of knees suggest atopic dermatitis. Hands and feet with blistering suggest dyshidrotic eczema. Scalp and facial creases suggest seborrheic dermatitis. Coin-shaped patches on the limbs suggest nummular eczema.
Is there a family history of eczema, asthma, or hay fever? A positive atopic family history is a strong pointer toward atopic dermatitis specifically.
Does it flare with specific exposures? Flares consistently associated with particular substances, materials, or environments suggest contact dermatitis and warrant patch testing.
How does it respond to treatment? Contact dermatitis typically does not fully clear with topical steroids alone if the exposure continues. Seborrheic dermatitis typically responds better to antifungals than to steroids alone.
What does the skin look like between flares? Dry, slightly rough skin between flares is consistent with atopic dermatitis. Normal-appearing skin that only becomes inflamed with specific exposures is more consistent with contact dermatitis.
The Treatment Implication, Restated Simply
If you have atopic dermatitis — a chronic, immune-mediated condition with a skin barrier defect — your treatment needs to address those two things consistently, not just suppress visible flares when they occur. Emollients every day. Appropriate anti-inflammatory therapy during flares. Consideration of immune modulation (phototherapy or systemic treatment) if topicals alone are not maintaining adequate control.
If you have contact dermatitis, your treatment needs to identify and remove the cause. Inflammation management without cause identification is indefinite symptom suppression.
If you have seborrheic dermatitis, your treatment needs an antifungal component. Anti-inflammatory treatment alone will not achieve lasting control.
The right diagnosis, made precisely, changes the treatment entirely. If you have been told you have eczema and have spent years managing symptoms without meaningful improvement, the most useful question to ask is whether the specific type has been confirmed — and whether the treatment you are receiving is actually matched to it.
UVThera home devices deliver 311nm NB-UVB phototherapy for atopic dermatitis, vitiligo, and psoriasis — with real dosimetry that ensures every session delivers exactly the prescribed dose, wherever you are. CDSCO Class B registered.
Speak to your dermatologist to confirm the type of eczema you have before beginning any treatment.